Efficacy and safety of switching to ixekizumab in secukinumab nonresponder psoriatic patients: results from a multicenter experience

Abstract

Loss of efficacy of biological therapies in psoriatic patients is a well‐known event. Biological switching is common in clinical practice, especially in TNF‐α and IL‐12/23 inhibitors treatment^1,2. Recently, anti‐IL‐17A drugs such as secukinumab have provided a new therapeutic opportunity

This article is protected by copyright. All rights reserved.

http://bit.ly/2EJXtqr